Vasovistâ„¢ is an albumin-targeted intravascular contrast agent. It is indicated for contrast enhanced MR angiography (CE-MRA) for the visualization of abdominal or limb vessels in patients with suspected or known vascular disease. After IV injection, Vasovistâ„¢ binds reversibly to human albumin in plasma, which results in long-lasting increased relaxivity. Imaging from 5 to 50 min is possible. A small unbound portion is, by glomerular filtration, eliminated by the kidneys.
AngioMARK® was the formerly trade name and MS-325 the research name. Currently the phase III clinical trials are completed to determine its efficacy for peripheral vascular disease and coronary artery disease.
In the U.S., EPIX received an approvable letter from the U.S. Food and Drug Administration (FDA) for Vasovistâ„¢ in January 2005. In 2009, Epix Pharmaceuticals has sold the U.S., Canadian and Australian rights for its blood pool agent (now named ABLAVARâ„¢), to Lantheus Medical Imaging, Inc..

WARNING: NEPHROGENIC SYSTEMIC FIBROSIS Gadolinium-based contrast agents increase the risk for nephrogenic systemic fibrosis (NSF) in patients with acute or chronic severe renal insufficiency (glomerular filtration rate less than 30 mL/min/1.73m²), or acute renal insufficiency of any severity due to the hepato-renal syndrome or the liver transplantation period.

See also MRI Safety.

From Hitachi Medical Systems America Inc.;
the AIRIS II, an entry in the diagnostic category of open MR systems, was designed by Hitachi Medical Systems America Inc. (Twinsburg, OH, USA) and Hitachi Medical Corp. (Tokyo) and is manufactured by the Tokyo branch. A 0.3 T field-strength magnet and phased array coils deliver high image quality without the need for a tunnel-type high-field system, thereby significantly improving patient comfort not only for claustrophobic patients.

From Hitachi Medical Systems America, Inc.;
the AIRIS made its debut in 1995. Hitachi followed up with the AIRIS II system, which has proven equally successfully. 'All told, Hitachi has installed more than 1,000 MRI systems in the U.S., holding more than 17 percent of the total U.S. MRI installed base, and more than half of the installed base of open MR systems,' says Antonio Garcia, Frost and Sullivan industry research analyst. Now Altaire employs a blend of innovative Hitachi features called VOSIâ„¢ technology, optimizing each sub-system's performance in concert with the other sub-systems, to give the seamless mix of high-field performance and the patient comfort, especially for claustrophobic patients, of open MR systems.

Short name: B22956, generic name: Gadocoletic acid, chemical compound: Gadocoletic acid trisodium salt, central moiety: Gd, phase: II
A blood pool agent for magnetic resonance coronary angiography and first pass myocardial perfusion imaging under development (Bracco Diagnostics Inc). The small molecules of gadolinium-based B22956 are bound after injection to large human serum albumin molecules in coronary vessels with the result of high vessel/muscle contrast.

From Siemens Medical Systems;

FDA cleared and CE Mark 2011.
The Biograph mMR has a fully-integrated design for simultaneous PET/MRI imaging. The dedicated hardware includes solid-state, avalanche photodiode PET detector and adapted, PET-compatible MR coils.
The possibility of truly simultaneous operation allows the acquisition of several magnetic resonance imaging (MRI) sequences during the positron emission tomography (PET) scan, without increasing the examination time.
See also Hybrid Imaging.